A Multi-center, Randomized, Double-blind, Placebo- Parallel Controlled, Phase II Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects
Latest Information Update: 25 Nov 2024
Price :
$35 *
At a glance
- Drugs HRS 9531 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Fujian Shengdi Pharmaceutical
- 21 Dec 2023 Planned End Date changed from 9 Sep 2024 to 20 Aug 2024.
- 21 Dec 2023 Planned primary completion date changed from 12 Aug 2024 to 30 Apr 2024.
- 21 Dec 2023 Status changed from recruiting to active, no longer recruiting.